久久婷婷国产综合精品,久久久久久久性潮,换脸国产av一区二区三区,韩国精品一区二区三区无码视频 ,久久久久成人精品无码

  • FDA accepts new drug application for Novartis’ Promacta pharmaceutical-technology
    June 01, 2018
    The FDA’s award of a priority review is based on Novartis’ study in which 52% of treatment-na?ve SAA patients achieved complete response at six months when treated with Promacta and standard IST.

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194
+86 15021993094

PharmaSources Customer Service